Informacija apie narį
Dr Marta Morales Ballús
Ispanija
Komanda
Dr Jaume Català Mora
Ispanija
Dr Elisa Carreras
Ispanija
Dr Itziar Alonso
Ispanija
Dr Isabel Ayet
Ispanija
Dr Ester Casas
Ispanija
Optometrist Ana Díaz
Ispanija
Dr Jesús Díaz
Ispanija
Optometrist Enric Puigventos
Ispanija
Optometrist Carles Fresno
Ispanija
Dr Carmen García Vicuña
Ispanija
Dr Hugo Gonzalez
Ispanija
Optometrist Enrique Jimenez
Ispanija
Dr Ana Llorca
Ispanija
Dr Antonio Federico Martinez Monstseny
Ispanija
Dr Joan Prat
Ispanija
Dr Gemma Romeu
Ispanija
Dr Alicia Serra
Ispanija
Optometrist Simone Suh
Ispanija
Dr Mariona Vidal
Ispanija
Optometrist Begoña Yeste
Ispanija
Dr Núria Planas
Ispanija
HCP centras
kontaktas
Hospital Sant Joan de Déu, Spain
Klinikiniai tyrimai
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation